LTG-001
Pain (specific type not disclosed)
Phase 1Active
Key Facts
About Latigo Biotherapeutics
Latigo Biotherapeutics is a private, clinical-stage biotech company pioneering a new class of non-opioid pain therapeutics. Its lead program, LTG-001, is a Nav1.8 inhibitor that has completed a Phase 1 trial, showing favorable safety and rapid absorption. The company leverages a proprietary discovery platform centered on human biology and ion channel expertise to develop peripherally-acting analgesics for a large and underserved market dominated by opioids.
View full company profile